Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Equity Ratio (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Equity Ratio readings, the most recent being 0.6 for Q4 2025.

  • On a quarterly basis, Equity Ratio rose 246.32% to 0.6 in Q4 2025 year-over-year; TTM through Dec 2025 was 0.6, a 246.32% increase, with the full-year FY2025 number at 0.6, up 246.32% from a year prior.
  • Equity Ratio hit 0.6 in Q4 2025 for Aligos Therapeutics, down from 0.65 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.83 in Q1 2021 to a low of 0.41 in Q4 2024.
  • Median Equity Ratio over the past 5 years was 0.7 (2023), compared with a mean of 0.64.
  • Biggest five-year swings in Equity Ratio: tumbled 168.02% in 2024 and later skyrocketed 246.32% in 2025.
  • Aligos Therapeutics' Equity Ratio stood at 0.78 in 2021, then dropped by 9.76% to 0.71 in 2022, then fell by 14.2% to 0.61 in 2023, then tumbled by 168.02% to 0.41 in 2024, then skyrocketed by 246.32% to 0.6 in 2025.
  • The last three reported values for Equity Ratio were 0.6 (Q4 2025), 0.65 (Q3 2025), and 0.76 (Q2 2025) per Business Quant data.